There is a caveat to your thinking.A BP who wants to partner or have some sort of deal for the whole (known) B platform will likely not want to wait until September and therefore give another BP a chance to cherry pick indications out from under them.
Compared to and considering BP's shelling out huge deals for companies with just pre-clinical drugs ,IPIX has enough data to satisfy BP decision-making already.

Kelt